“Cancer 2015”: A prospective, population-based cancer cohort—phase 1: Feasibility of genomics-guided precision medicine in the clinic

Journal of Personalized Medicine

Volumn 5, Issue 4, 2015, Pages 354-369

  Parisot, John P ^a,b   Thorne, Heather ^a,b   Fellowes, Andrew ^a   Doig, Ken ^a,b   Lucas, Mark ^c   McNeil, John J ^c   Doble, Brett ^c   Dobrovic, Alexander ^a,b,d,e   John, Thomas ^d,e   James, Paul A ^a   Lipton, Lara ^f   Ashley, David ^g   Hayes, Theresa ^h   McMurrick, Paul ⁱ   Richardson, Gary ⁱ   Lorgelly, Paula ^c   Fox, Stephen B ^a,b   Thomas, David M ^a,b,j  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d OLIVIA NEWTON JOHN CANCER RESEARCH INSTITUTE   (Australia)

^e LA TROBE UNIVERSITY   (Australia)

^f ROYAL MELBOURNE HOSPITAL   (Australia)

^g GEELONG HOSPITAL   (Australia)

^h Department of General Surgery   (Australia)

ⁱ CABRINI INSTITUTE   (Australia)

^j GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

more..

Author keywords

Cancer genomics cohort; Health economics; Next Gen sequencing; Precision medicine

Indexed keywords

ADULT; ARTICLE; CANCER INCIDENCE; CANCER RADIOTHERAPY; CLINICAL PRACTICE; EVALUATION AND FOLLOW UP; FEASIBILITY STUDY; FEMALE; GENOMICS; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEOPLASM; OUTCOME ASSESSMENT; POPULATION BASED CASE CONTROL STUDY; QUESTIONNAIRE; SOMATIC MUTATION;

EID: 84977262759     PISSN: None     EISSN: 20754426     Source Type: Journal    
DOI: 10.3390/jpm5040354     Document Type: Article

References (21)

1. Stewart, B.W.; Wild, C. World Cancer Report 2014. International Agency for Research on Cancer; World Health Organization: Lyon, France, 2014.
2. Cancer Council of Victoria Cancer Registry. Cancer in Victoria: Statistics and Trends. Available online: http://www.cancervic.org.au/research/registry-statistics/cancer-in-victoria (accessed on 21 September 2015).
3. Callaway, E. Norway to bring cancer-gene tests to the clinic. Nature 2012, doi:10.1038/nature. 2012.9949.
4. Rabesandratana, R. U.K.'s 100,000 Genomes Project Gets £ 300 Million to Finish the Job by 2017. Available online: http://news.sciencemag.org/biology/2014/08/u-k-s-100000-genomes-project-gets-300-million-finish-job-2017 (accessed on 22 October 2015).
5. The Academy of Medical Sciences. Realising the Potential of Stratified Medicine. July 2013. Available online: http://www.acmedsci.ac.uk/policy/policy-projects/Stratified-medicine/ (accessed on 22 October 2015).
6. Australian Institute of Health and Welfare and Australasian Association of Cancer Registries 2012. Cancer in Australia: An Overview 2012; AIHW: Canberra, Australia, 2012.
7. Health Data Standards Committee. Data Set Specification, National Health Data Dictionary version 12 Supplement. Available online: http://www.aihw.gov.au/publication-detail/?id=6442467641 (accessed on 21 September 2015).
8. Oken, M.M.; Creech, R.H.; Tormey, D.C.; Horton, J.; Davis, T.E.; McFadden, E.T. Carbone, P.P. Toxicity and response criteria of the eastern cooperative oncology group. Am. J. Clin. Oncol. 1982, 5, 649-655.
9. Charlson, M.E.; Pompei, P.; Ales, K.L.; MacKenzie, C.R. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J. Chronic Dis. 1987, 40, 373-383.
10. Wong, S.Q.; Li, J.; Tan, A.Y.-C.; Vedururu, R.; Pang, J.-M.B.; Do, H.; Ellul, J.; Doig, K.; Bell, A.; McArthur, G.A.; et al. Sequence artefacts in a prospective series of formalin-fixed tumours tested for mutations in hotspot regions by massively parallel sequencing. BMC Med. Genomics 2014, doi:10.1186/1755-8794-7-23.
11. Mitra, A.; Mishra, L.; Li, S. EMT, CTCs and CSCs in tumor relapse and drug-resistance. Oncotarget 2015, 6, 10697-10711.
12. Wong, S.Q.; Fellowes, A.; Doig, K.; Ellul, J.; Bosma, T.; Vedururu, R.; Tan, A.Y.-C.; Weiss, J.; Chan, K.S.; Lucas, M.; et al. Assessing the clinical value of targeted massively parallel sequencing in a longitudinal, prospective population-based study of cancer patients. Br. J. Cancer 2015, 112, 1411-1420.
13. Lopez-Chavez, A.; Thomas, A.; Rajan, A.; Raffeld, M.; Morrow, B.; Kelly, R.; Carter, C.A.; Guha, U.; Killian, K.; Lau, C.C.; et al. Molecular profiling and targeted therapy for advanced thoracic malignancies: A biomarker-derived, multiarm, multihistology phase II basket trial. J. Clin. Oncol. 2015, 33, 1000-1007.
14. Meric-Bernstam, F.; Brusco, L.; Shaw, K.; Horombe, C.; Kopetz, S.; Davies, M.A.; Routbort, M.; Piha-Paul, S.A.; Janku, F.; Ueno, N.; et al. Feasibility of large-scale genomic testing to facilitate enrollment onto genomically matched clinical trials. J. Clin. Oncol. 2015, 33, 2753-2762.
15. Hyman, D.M.; Puzanove, I.; Subbiah, V.; Faris, J.E.; Chau, I.; Blay, J.-Y.; Wolf, J.; Raje, N.S.; Diamond, E.L.; Hollebecque, A.; et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N. Engl. J. Med. 2015, 373, 726-736.
16. Beltran, H.; Eng, K.; Mosquera, J.M.; Sigaras, A.; Romanel, A.; Rennart, H.; Kossai, M.; Pauli, C.; Faltas, B.; Fontugne, J.; et al. Whole-exome sequencing of metastatic cancer and biomarkers of treatment response. JAMA Oncol. 2015, 4, 466-474.
17. Schott, A.F.; Perou, C.M.; Hayes, D.F. Genome medicine in cancer: What's in a name? Cancer Res. 2015, 75, 1930-1935.
18. Erdmann, J. All aboard: Will molecular tumor boards help cancer patients? Nat. Med. 2015, 21, 655-656.
19. National Health and Medical Research Council. National Statement on Ethical Conduct in Human Research (2007). Available online: https://www.nhmrc.gov.au/guidelines-publications/e72 (accessed on 21 September 2015).
20. Aaronson, N.K.; Ahmedzai, S.; Bergman, B.; Bullinger, M.; Cull, A.; Duez, N.J.; Filiberti, A.; Flechtner, H.; Fleishman, S.B.; de Haes, J.C.J.M.; et al. The European organization for research and treatment of cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J. Natl. Cancer Inst. 1993, 85, 365-376.
21. Brooks, R. EuroQol: The current state of play. Health Policy 1996, 37, 53-72.